The Roche, Novartis and Kraft Group-backed, protein degradation-focused drug developer received $150m in series B funding and $20m in venture debt.
C4 Therapeutics, a US-based small molecule drug developer backed by diversified conglomerate Kraft Group and pharmaceutical firms Roche and Novartis, completed a $170m financing round yesterday.
Investment firm Cobro Ventures and hedge fund Perceptive Advisors co-led the $150m series B equity portion of the round, which also featured undisclosed existing investors, while Perceptive Advisors also supplied $20m in debt financing.
Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos…
